Single-cell genotyping of MDS/CMML clonal output, VTE risk in diffuse glioma, and Del(1p32) is an adverse prognostic factor in myeloma

Blood Podcast

English - March 16, 2023 16:30 - 20 minutes - 19.1 MB - ★★★★ - 44 ratings
Life Sciences Science hematology oncology medical medical research Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: RUNX1 isoform imbalance drives ML-DS, VWF-binding RNA aptamer for hemophilia A treatment, and EZH1/2 inhibitor valemetostat in relapsed/refractory ATL

Next Episode: Anti-malaria benefit of hydroxyurea in SCA, IL-22 in the treatment in lower GI acute GVHD, and FLT3-ITD changes depend on context in AML

In this week’s episode we’ll discuss how azacytidine therapy influences the contributions of mutated HSC clones to hematopoiesis in MDS and CMML, learn more about the risk of venous thromboembolism in patients with adult-type diffuse glioma, and discuss the importance of 1p32 deletions as an independent and adverse prognostic factor in myeloma.